Salt Lake City, Utah – The CAR T cell therapy niche has certainly provided plenty of controversy, highlights and lowlights over the last decade or so, although much of the mainstream attention has really only surfaced in the last couple of years.
For those interested in this space, there is a short synopsis of the BMT Tandem 2018 plenary session that took place this weekend and simultaneously published in the ASBMT journal (See: Perales et al., 2018):
“Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR”
While no one doubts that we have a need for safer CARs to reduce or ameliorate severe toxicities (the debate here is what are the best ways to achieve that in the clinic), it remains unclear whether a fast or slow approach is the optimal way forward in terms of efficacy.
In this post, we take a look at new clinical and scientific findings that may pave the way forward for the future in the CAR T cell space through the lens of several different academic institutions…
To learn more from thought leaders and get a heads up on our latest oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
Salt Lake City – at the 2018 BMT Tandem meeting (Twitter: #BMTTandem18) the combined annual meeting of the American Society for Blood and Marrow Transplantation (ASBMT) and Center for International Blood & Marrow Transplant Research (CIBMTR), one of the presentations of note today was a 7am breakfast symposium entitled:
“Realizing the Promise of CAR T cell Therapy for Leukemia and Lymphoma: Implications for Long-term Care in the Era of Stem Cell Transplantation.”
Cancer cells in culture Source: Dr Cecil Fox, National Cancer Institute
This educational session supported by grants from Kite/Gilead and Novartis, featured two BMT transplant experts with hands-on experience of CAR T cell trials: Dr Stephan Grupp (@GruppSteve) from The Children’s Hospital of Philadelphia and Dr Krishna Komanduri (@drkomanduri) from the University of Miami Sylvester Comprehensive Cancer Center.
We’ve previously interviewed both Dr Grupp and Dr Komanduri on BSB, so were keen to hear how leading transplanters view the CAR T landscape now that two therapies have been approved by the FDA, and how they think this approach will integrate with transplants, and which patients will benefit most from this therapy.
Subscribers can log-in to read the take-homes we took from this session or if you didn’t make it to Salt Lake City, can click to gain access to BSB Premium Content.